SPDR MSCI ACWI ex-US ETF (CWI)
NYSEArca - NYSEArca Delayed Price. Currency in USD
- Market Realist•last month
In 2016, Teva Pharmaceutical (TEVA) expects to earn revenues of $22.0 billion–$22.5 billion. This includes contribution from sales of Allergan Generics products.
- ETF Trends•2 months ago
People should begin to lower expectations after years of fast and high growth. In the new low-growth environment ahead, exchange traded fund investors, though, may find higher returns in international ...
- Market Realist•3 months ago
Teva Pharmaceutical expects to benefit from improved productivity after the completion of the deal with Actavis Generics.